|
Jun 18
|
Mirum (MIRM) Soars on Interim Data From Liver Disease Studies
|
|
Jun 18
|
Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?
|
|
Jun 17
|
Mirum Pharmaceuticals Advances after Reporting Positive Trial Results for Prospective Cholangitis Treatment
|
|
Jun 17
|
Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
|
|
Jun 16
|
Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024
|
|
Jun 7
|
Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report?
|
|
Jun 6
|
Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress
|
|
Jun 5
|
Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
|
|
May 18
|
Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
|
|
May 13
|
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2024 Earnings Call Transcript
|
|
May 10
|
Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings: Misses Revenue Forecasts, Posts Wider Net Loss
|
|
May 9
|
Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates
|
|
May 9
|
Q1 2024 Mirum Pharmaceuticals Inc Earnings Call
|
|
May 9
|
Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings Call Transcript Highlights: Soaring Sales and ...
|
|
May 8
|
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 7
|
Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
|
|
May 7
|
Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
|
|
May 2
|
Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management
|
|
May 1
|
Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
|
|
Apr 30
|
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
|